| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| SDZ.SW - | HOLD | 0 @ CHF 59.5223 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 59.5223. The average price that SDZ.SW shares were previous bought at was CHF 44.1701. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 491 (USD $618) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 130.6 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 130.6. The average price that IPN.PA shares were previous bought at was EUR 103.683. The current market price is 26.0% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 15,542 (USD $18,053) compared to the previous valuation of Ipsen SA |
| LONN.SW - | HOLD | 0 @ CHF 584.602 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 584.602. The average price that LONN.SW shares were previous bought at was CHF 606.416. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 186,729 (USD $235,092) compared to the previous valuation of |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 115.75 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 115.75. The average price that MRK.DE shares were previous bought at was EUR 115.858. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in MRK.DE has fallen by EUR 99,014 (USD $115,008) compared to the previous valuation of Merck KGaA |
| NOVN.SW - | HOLD | 0 @ CHF 114.644 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 114.644. The average price that NOVN.SW shares were previous bought at was CHF 101.338. The current market price is 13.1% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 1,074,752 (USD $1,353,115) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 41.8706 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 41.8706. The average price that NOVO-B.CO shares were previous bought at was DKK 63.2354. The current market price is -33.8% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 299,699 (USD $46,622) compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| NSIS-B.CO - | HOLD | 0 @ DKK 54.7786 | DKK 0 | The current share valuation price of NSIS-B.CO based on adjusted close was DKK 54.7786. The average price that NSIS-B.CO shares were previous bought at was DKK 61.0647. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in NSIS-B.CO has fallen by DKK 95,753 (USD $14,896) compared to the previous valuation of |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 60.15 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 60.15. The average price that ORNBV.HE shares were previous bought at was EUR 60.1932. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 6,921 (USD $8,039) compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 24.34 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 24.34. The average price that PHIA.AS shares were previous bought at was EUR 21.0294. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 146,167 (USD $169,778) compared to the previous valuation of Koninklijke Philips NV |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 38.15 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 38.15. The average price that QIA.DE shares were previous bought at was EUR 42.5094. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 1,388 (USD $1,612) compared to the previous valuation of QIAGEN NV |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 52.25 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 52.25. The average price that REC.MI shares were previous bought at was EUR 53.4467. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in REC.MI has fallen by EUR 25,853 (USD $30,029) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA |
| ROG.SW - | HOLD | 0 @ CHF 311.268 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 311.268. The average price that ROG.SW shares were previous bought at was CHF 281.464. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 225,078 (USD $283,374) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 89.89 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 89.89. The average price that SAN.PA shares were previous bought at was EUR 88.9526. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 145,256 (USD $168,720) compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.19789 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.19789. The average price that HLN.L shares were previous bought at was GBP 4.56586. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 90,371 (USD $118,930) compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 26.2015 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 26.2015. The average price that SECT-B.ST shares were previous bought at was SEK 29.0373. The current market price is -9.8% lower than average price they were purchased at. The value of the holding in SECT-B.ST has fallen by SEK 13,901 (USD $1,471) compared to the previous valuation of |
| SFZN.SW - | HOLD | 0 @ CHF 76.9499 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 76.9499. The average price that SFZN.SW shares were previous bought at was CHF 105.102. The current market price is -26.8% lower than average price they were purchased at. The value of the holding in SFZN.SW has fallen by CHF 74,745 (USD $94,104) compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 41.78 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 41.78. The average price that SHL.DE shares were previous bought at was EUR 47.9251. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 289,843 (USD $336,663) compared to the previous valuation of Siemens Healthineers AG |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 14.1445 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 14.1445. The average price that SN.L shares were previous bought at was GBP 12.7572. The current market price is 10.9% higher than average price they were purchased at. The value of the holding in SN.L has increased by GBP 6,447 (USD $8,484) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 30.6838 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 30.6838. The average price that SOBI.ST shares were previous bought at was SEK 26.4967. The current market price is 15.8% higher than average price they were purchased at. The value of the holding in SOBI.ST has fallen by SEK 33,469 (USD $3,543) compared to the previous valuation of |
| SOON.SW - | HOLD | 0 @ CHF 216.381 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 216.381. The average price that SOON.SW shares were previous bought at was CHF 271.632. The current market price is -20.3% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 75,817 (USD $95,454) compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 228.2 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 228.2. The average price that SRT3.DE shares were previous bought at was EUR 215.217. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 22,376 (USD $25,990) compared to the previous valuation of Sartorius AG |
| STMN.SW - | HOLD | 0 @ CHF 106.451 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 106.451. The average price that STMN.SW shares were previous bought at was CHF 113.693. The current market price is -6.4% lower than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 143,049 (USD $180,099) compared to the previous valuation of |
| TECN.SW - | HOLD | 0 @ CHF 150.215 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 150.215. The average price that TECN.SW shares were previous bought at was CHF 178.532. The current market price is -15.9% lower than average price they were purchased at. The value of the holding in TECN.SW has fallen by CHF 9,451 (USD $11,899) compared to the previous valuation of |
| TUB.BR - Financiere de Tubize SA | HOLD | 0 @ EUR 199.8 | EUR 0 | The current share valuation price of TUB.BR based on adjusted close was EUR 199.8. The average price that TUB.BR shares were previous bought at was EUR 128.453. The current market price is 55.5% higher than average price they were purchased at. The value of the holding in TUB.BR has fallen by EUR 10,835 (USD $12,585) compared to the previous valuation of Financiere de Tubize SA |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 228.6 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 228.6. The average price that UCB.BR shares were previous bought at was EUR 162.822. The current market price is 40.4% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 89,590 (USD $104,062) compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| ZEAL.CO - | HOLD | 0 @ DKK 70.2173 | DKK 0 | The current share valuation price of ZEAL.CO based on adjusted close was DKK 70.2173. The average price that ZEAL.CO shares were previous bought at was DKK 58.9926. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in ZEAL.CO has increased by DKK 39,322 (USD $6,117) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 28.6547 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 28.6547. The average price that DEMANT.CO shares were previous bought at was DKK 35.6031. The current market price is -19.5% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 17,351 (USD $2,699) compared to the previous valuation of |
| ALC.SW - | HOLD | 0 @ CHF 66.5454 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 66.5454. The average price that ALC.SW shares were previous bought at was CHF 77.6685. The current market price is -14.3% lower than average price they were purchased at. The value of the holding in ALC.SW has fallen by CHF 89,171 (USD $112,266) compared to the previous valuation of |
| ALK-B.CO - | HOLD | 0 @ DKK 31.6005 | DKK 0 | The current share valuation price of ALK-B.CO based on adjusted close was DKK 31.6005. The average price that ALK-B.CO shares were previous bought at was DKK 23.6007. The current market price is 33.9% higher than average price they were purchased at. The value of the holding in ALK-B.CO has increased by DKK 43,863 (USD $6,823) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| AMBU-B.CO - | HOLD | 0 @ DKK 11.4284 | DKK 0 | The current share valuation price of AMBU-B.CO based on adjusted close was DKK 11.4284. The average price that AMBU-B.CO shares were previous bought at was DKK 13.8673. The current market price is -17.6% lower than average price they were purchased at. The value of the holding in AMBU-B.CO has fallen by DKK 548 (USD $85) compared to the previous valuation of |
| AMP.MI - Amplifon SpA | HOLD | 0 @ EUR 13.44 | EUR 0 | The current share valuation price of AMP.MI based on adjusted close was EUR 13.44. The average price that AMP.MI shares were previous bought at was EUR 20.2713. The current market price is -33.7% lower than average price they were purchased at. The value of the holding in AMP.MI has fallen by EUR 11,650 (USD $13,532) compared to the previous valuation of Amplifon SpA |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 792.4 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 792.4. The average price that ARGX.BR shares were previous bought at was EUR 508.161. The current market price is 55.9% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 327,840 (USD $380,797) compared to the previous valuation of Argenx SE however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 154.419 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 154.419. The average price that AZN.L shares were previous bought at was GBP 125.063. The current market price is 23.5% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 856,896 (USD $1,127,688) compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 24.6444 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 24.6444. The average price that BAVA.CO shares were previous bought at was DKK 22.8997. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 34,377 (USD $5,348) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 27.945 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 27.945. The average price that BAYN.DE shares were previous bought at was EUR 25.4056. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in BAYN.DE has fallen by EUR 192,122 (USD $223,156) compared to the previous valuation of Bayer AG |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 106.4 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 106.4. The average price that BIM.PA shares were previous bought at was EUR 119. The current market price is -10.6% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 24,670 (USD $28,655) compared to the previous valuation of BioMerieux |
| CAMX.ST - | HOLD | 0 @ SEK 56.6667 | SEK 0 | |
| COLO-B.CO - | HOLD | 0 @ DKK 76.8588 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 76.8588. The average price that COLO-B.CO shares were previous bought at was DKK 86.1309. The current market price is -10.8% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 132,092 (USD $20,549) compared to the previous valuation of |
| CTEC.L - ConvaTec Group PLC | HOLD | 0 @ GBP 2.71755 | GBP 0 | The current share valuation price of CTEC.L based on adjusted close was GBP 2.71755. The average price that CTEC.L shares were previous bought at was GBP 3.26342. The current market price is -16.7% lower than average price they were purchased at. The value of the holding in CTEC.L has fallen by GBP 44,929 (USD $59,127) compared to the previous valuation of ConvaTec Group PLC |
| ABVX.PA - Abivax SA | HOLD | 0 @ EUR 97.2 | EUR 0 | |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 58.86 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 58.86. The average price that DIA.MI shares were previous bought at was EUR 95.1491. The current market price is -38.1% lower than average price they were purchased at. The value of the holding in DIA.MI has fallen by EUR 662 (USD $769) compared to the previous valuation of DiaSorin SpA |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 190.05 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 190.05. The average price that DIM.PA shares were previous bought at was EUR 198.449. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 32,279 (USD $37,493) compared to the previous valuation of Sartorius Stedim Biotech |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 315.6 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 315.6. The average price that EL.PA shares were previous bought at was EUR 248.629. The current market price is 26.9% higher than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 439,068 (USD $509,993) compared to the previous valuation of EssilorLuxottica SA |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 58.72 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 58.72. The average price that ERF.PA shares were previous bought at was EUR 57.9209. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in ERF.PA has fallen by EUR 12,085 (USD $14,037) compared to the previous valuation of Eurofins Scientific SE |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 40.09 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 40.09. The average price that FME.DE shares were previous bought at was EUR 47.8642. The current market price is -16.2% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 32,134 (USD $37,325) compared to the previous valuation of Fresenius Medical Care AG |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 48.85 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 48.85. The average price that FRE.DE shares were previous bought at was EUR 42.5137. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 22,768 (USD $26,446) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 158.668 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 158.668. The average price that GALD.SW shares were previous bought at was CHF 119.169. The current market price is 33.1% higher than average price they were purchased at. The value of the holding in GALD.SW has fallen by CHF 206,683 (USD $260,214) compared to the previous valuation of |
| GETI-B.ST - | HOLD | 0 @ SEK 19.3323 | SEK 0 | The current share valuation price of GETI-B.ST based on adjusted close was SEK 19.3323. The average price that GETI-B.ST shares were previous bought at was SEK 17.2685. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in GETI-B.ST has fallen by SEK 27,653 (USD $2,927) compared to the previous valuation of |
| GMAB.CO - | HOLD | 0 @ DKK 264.52 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 264.52. The average price that GMAB.CO shares were previous bought at was DKK 186.369. The current market price is 41.9% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 80,191 (USD $12,475) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 10.585 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 10.585. The average price that GRF.MC shares were previous bought at was EUR 10.3964. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 9,394 (USD $10,911) compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 20.4441 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 20.4441. The average price that GSK.L shares were previous bought at was GBP 16.9988. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 445,974 (USD $586,908) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 17.9163 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 17.9163. The average price that HIK.L shares were previous bought at was GBP 23.9671. The current market price is -25.2% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 4,962 (USD $6,530) compared to the previous valuation of however if the holding was sold on 2025-11-17 this would crystalise an overall loss. |